BioSig's Streamex Deal Creates $105.5M Exchangeable-Share Liability, Triggers Going Concern

BioSig Technologies, Inc. (OTCMKTS: BSGM) - quick internal/financial snapshot

The company completed the May 28, 2025 acquisition of Streamex, reallocated management (new CEO Henry McPhie), and recorded large purchase accounting items (goodwill, intangibles) and a sizable derivative liability tied to Exchangeable Shares. Management is raising capital (ATM, registered public offering, debenture/SEPA deals) while the business remains largely pre-revenue and flagged with going-concern risk and material internal-control weaknesses.

Key facts & statistics (as presented)
* Cash (June 30, 2025): $2,820,000
* Total assets: $109,721,000
* Working capital deficit: ≈ $110 million (note: current liabilities jump driven by derivative liability)
* Derivative liability (Exchangeable Shares, May 28, 2025): $105,498,000
* Intangible assets, net: $47,917,000; Goodwill: $58,692,000 (from Streamex acquisition)
* Accounts payable & accrued expenses (June 30, 2025): $7,572,000 (includes a $6.026M finder-fee accrual)
* Revenue: $0 for three and six months ended June 30, 2025 (prior year: $13 and $27)
* Loss from operations: $(20,365,000) for Q2 2025; $(23,350,000) for six months 2025
* Net loss attributable to common shareholders: $(20,374,000) Q2 2025; $(23,190,000) six months 2025
* Net loss per share, basic & diluted: $(0.74) Q2 2025; $(0.95) six months 2025
* Weighted average common shares: 27,706,780 (Q2 2025); 24,286,234 (6‑mo 2025)
* Stock-based compensation (G&A & RSUs): ~$14.2M for six months ended June 30, 2025 (RSU-related expense $13.74M); G&A stock-based comp $12.12M for Q2 2025
* Cash used in operating activities (six months): $(2,393,000)
* ATM proceeds (6 months): $3,882,420 net; Aug 15, 2025 public offering: gross ~$15.0M / net ~$13.62M (subsequent event)
* Exchangeable Shares issued in acquisition: 109,070,079 (convertible into BioSig common stock subject to conditions/approvals)
* Shares outstanding: 30,793,135 at June 30, 2025; 31,418,795 as of Aug 14, 2025 per filing
* Material weaknesses in internal control disclosed (stock-comp accounting, period-end review, segregation of duties)

What's happening inside the company - the short version
* Strategic pivot and acquisition: BioSig bought Streamex (May 28, 2025) to expand into tokenization/blockchain infrastructure. Acquisition drove large one-time non-cash amounts (goodwill, intangibles) and created the Exchangeable Shares derivative liability that dominates the balance sheet.
* Management change and compensation: New CEO (former Streamex CEO); accelerated and large equity grants/RSUs to executives and consultants (material non-cash expense and dilution).
* Financing push: active equity raises (ATM sales, March/May financings, Aug 15 public offering) and contingent financing agreements (Yorkville debentures, SEPA) to address liquidity shortfall.
* Controls & governance: company disclosed material weaknesses in internal controls - risk for reporting errors and investor concern.

Positive aspects of the income statement / cash picture
* Cash burn (cash flow) is materially lower than GAAP loss: six‑month operating cash outflow was $(2.39M) despite a $(23.17M) GAAP loss - much of the GAAP loss is non‑cash (stock‑based comp, amortization from acquisition).
* Company has been able to raise equity (ATM sales $3.88M net in H1; March and May private placements; Aug 15 public offering ~$13.62M net subsequently) and has negotiated larger financing facilities (debenture/SEPA) to extend runway.
* R&D expense materially reduced (R&D $19k in Q2 2025 vs $342k prior-year quarter) - lower near-term cash payroll/R&D outlays.

Negative aspects of the income statement / financial risks
* Zero reported product revenue for the quarter and six months ended June 30, 2025 - commercial traction remains minimal.
* Large recurring G&A driven by equity-based compensation and one-time transaction costs: G&A $19.79M in Q2 2025 (vs $4.91M prior year), with $12.12M stock‑based comp in Q2 - inflates GAAP loss and signals heavy dilution.
* Heavy non-operating and balance-sheet risk: $105.5M derivative liability tied to Exchangeable Shares - significant contingent dilution and remeasurement volatility if assumptions change or shareholder approvals fail.
* Substantial doubt about going concern: cash $2.82M at June 30, 2025 with a working capital deficit ~ $110M - the company depends on external financing.
* Material weaknesses in internal controls increase risk of restatements or reporting delays and may hurt access to capital or listings.
* Large, immediate dilution risk: issuance of millions of shares for services/RSUs/warrants in 2025 and conversion features that can expand share count (including adjustment to 1.25x exchange ratio if shareholder approvals are not obtained).

Near-term items to watch
* Outcome of shareholder votes required to lift conversion caps on Exchangeable Shares (conversion cap, potential 1.25x adjustment if approval not obtained by deadline).
* Fair value remeasurement of the $105.5M derivative liability - large swings possible and P&L‑sensitive.
* Progress on Streamex commercialization (currently pre‑revenue) and any revenue recognition from tokenized product launches.
* Execution of financing arrangements (Yorkville debentures, SEPA) and the timing/conditions for accessing those proceeds; successful integration of Aug 15 public offering proceeds into runway.
* Remediation of internal-control weaknesses and external auditor scrutiny.

Bottom line (straightforward)
BioSig (OTCMKTS: BSGM) is in a transformational but risky phase. The Streamex acquisition materially changed the balance sheet and expense profile (big goodwill, intangibles, and a $105.5M derivative liability). GAAP losses are large, driven largely by non‑cash stock compensation and acquisition amortization; cash burn is much smaller but runway remains limited without additional financing. Key execution and governance risks (going concern doubt, control weaknesses, conversion contingencies) mean the company is highly dependent on successful financings and shareholder actions over the next months.

If you need a one‑page table/diagram of the numbers above or a short Q&A for investors, I can prepare it.